Super active surveillance for low-risk prostate cancer | Opinion: No

Super active surveillance for low-risk prostate cancer | Opinion: No

Bibliographic Details
Main Authors:	Saum Ghodoussipour, Amir Lebastchi, Peter Pinto, Andre Berger
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia
Series:	International Brazilian Journal of Urology
Subjects:	Prostatic Neoplasms Risk Reduction Behavior Watchful Waiting Therapeutics
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000200215&lng=en&tlng=en

Similar Items

Super active surveillance for low-risk prostate cancer | Opinion: Yes
by: Leonardo O. Reis, et al.

Current status of active surveillance in prostate cancer
by: Mun Su Chung, et al.
Published: (2016-01-01)

Active surveillance in intermediate risk prostate cancer: is it safe?
by: Nishanth Krishnananthan, et al.
Published: (2016-06-01)

Active surveillance in intermediate risk prostate cancer: is it safe?
by: Henk G. van der Poel, et al.
Published: (2016-06-01)

A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up
by: Sang Hun Song, et al.
Published: (2021-01-01)

Predicting Insignificant Prostate Cancer: Analysis of the Pathological Outcomes of Candidates for Active Surveillance according to the Pre-International Society of Urological Pathology (Pre-ISUP) 2014 Era Versus the Post-ISUP2014 Era
by: Mun Su Chung, et al.
Published: (2021-07-01)

Updated clinical results of active surveillance of very-low-risk prostate cancer in Korean men: 8 years of follow-up
by: Ji Yong Ha, et al.
Published: (2017-05-01)

MRI should be routine for all patients with localized prostate cancer? | Opinion: No
by: Joel B. Nelson

MRI should be routine for all patients with localized prostate cancer? | Opinion: Yes
by: Ronaldo Hueb Baroni

Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable‐risk prostate cancer
by: Da Huang, et al.
Published: (2023-04-01)

The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy
by: Wan Song, et al.
Published: (2019-11-01)

The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance
by: Chang Wook Jeong, et al.
Published: (2014-12-01)

The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
by: Hanfeng Wang, et al.
Published: (2017-09-01)

Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
by: Min Ji Jeon, et al.
Published: (2021-08-01)

Radical prostatectomy for high-risk prostate cancer | Opinion: NO
by: Saum Ghodoussipour, et al.

Active surveillance of atypical cartilaginous tumours of bone: short term quality of life measurements
by: Claudia Deckers, et al.
Published: (2023-03-01)

Active surveillance for nonmuscle invasive bladder cancer
by: Makito Miyake, et al.
Published: (2016-06-01)

Current Status of “Watch-and-Wait” Rectal Cancer Treatment in Asia-Pacific Countries
by: Jung Wook Huh, et al.
Published: (2020-04-01)

Active surveillance of renal masses: an analysis of growth kinetics and clinical outcomes stratified by radiological characteristics at diagnosis
by: Ryan Dorin, et al.
Published: (2014-10-01)

Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer Across US Census Regions
by: Bashir Al Hussein Al Awamlh, et al.
Published: (2021-05-01)

Ultrasound in active surveillance for low-risk papillary thyroid cancer: imaging considerations in case selection and disease surveillance
by: Sangeet Ghai, et al.
Published: (2021-09-01)

Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines
by: Min Joo Kim, et al.
Published: (2024-02-01)

The comparison of survival between active surveillance or watchful waiting and focal laser ablation in patients with low-risk prostate cancer
by: Jia-Kun Li, et al.
Published: (2022-01-01)

Prevalence and Management of Incidental Testicular Masses—A Systematic Review
by: Daniel Henriques, et al.
Published: (2022-09-01)

Midterm MRI Follow-Up of Untreated Enchondroma and Atypical Cartilaginous Tumors in the Long Bones
by: Claudia Deckers, et al.
Published: (2021-08-01)

Watch and Wait, Worth It?
by: Manoel Álvaro de Freitas Lins Neto, et al.
Published: (2022-12-01)

Small renal masses in the elderly: Contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies
by: Malte W. Vetterlein, et al.
Published: (2016-07-01)

Oncologic Outcomes of Organ Preserving Approaches in Patients With Rectal Cancer Treated With Preoperative Chemoradiotherapy
by: In Ja Park, et al.
Published: (2019-04-01)

The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database
by: Qi-Ming Yuan, et al.
Published: (2022-01-01)

Editorial: Challenging dogma: evolution in endourological techniques and management
by: Wesley Yip, et al.
Published: (2023-07-01)

Watch and wait strategies for rectal cancer: A systematic review
by: In Ja Park
Published: (2022-06-01)

Opinion: leading position of ultrasound in decision algorithm for small papillary thyroid carcinoma
by: Pierre Yves Marcy, et al.
Published: (2022-06-01)

Usefulness of close surveillance for rectal cancer patients after neoadjuvant chemoradiotherapy
by: Hsu Yu-Jen, et al.
Published: (2022-09-01)

Rectal Sparing Approaches after Neoadjuvant Treatment for Rectal Cancer: A Systematic Review and Meta-Analysis Comparing Local Excision and Watch and Wait
by: Quoc Riccardo Bao, et al.
Published: (2023-01-01)

Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort study
by: Philippe P. Bulens, et al.
Published: (2022-09-01)

The outcome of watchful waiting in patients with previously treated follicular lymphoma
by: Takahiro Fujino, et al.
Published: (2022-05-01)

Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: YES
by: Luiz Otavio Torres

Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: Not Yet
by: Marcelo Langer Wroclawski, et al.

Watchful Waiting in Pediatric Acute Otitis Media: A Real Practice Approach or an Intangible Desideratum?
by: Elena-Lia Spoială, et al.
Published: (2023-03-01)

Extra-abdominal desmoid tumours – further evidence for the watchful waiting policy
by: Andreas H. Krieg, et al.
Published: (2019-07-01)